Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index; 25 of the 47 sources its claims cite were checked for support.

Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials

Open access
Mosenzon, Ofri, Capehorn, Matthew S., De Remigis, Alessandra, Rasmussen, Søren, Weimers, Petra, Rosenstock, Julio · 2022 · Cardiovascular Diabetology

Abstract

Abstract Background Exploratory analysis to determine the effect of semaglutide versus comparators on high-sensitivity C-reactive protein (hsCRP) in subjects with type 2 diabetes. Methods Trials of once-weekly subcutaneous (SUSTAIN 3) and once-daily oral (PIONEER 1, 2, 5) semaglutide with hsCRP data were analyzed. Subjects with type 2 diabetes (N = 2482) received semaglutide (n = 1328) or comparators (placebo, n = 339; exenatide extended-release, n = 405; empagliflozin, n = 410). hsCRP ratio to baseline at end-of-treatment was analyzed overall, by clinical cutoff (< 1.0, ≥ 1.0 to ≤ 3.0, or > 3.0 mg/L), by tertile, and by estimated glomerular filtration rate in PIONEER 5 (a trial which was conducted in a population with type 2 diabetes and chronic kidney disease [CKD]). Mediation analyses assessed the effect of change in glycated hemoglobin (HbA 1c ) and/or change in body weight (BW) on hsCRP reductions. Results Geometric mean baseline hsCRP was similar across trials (range 2.7–3.0 mg/L). Semaglutide reduced hsCRP levels by clinical cutoffs and tertiles from baseline to end-of-treatment in all trials versus comparators (estimated treatment ratios [ETRs] versus comparators: 0.70–0.76; p < 0.01) except versus placebo in PIONEER 5 (ETR [95% CI]: 0.83 [0.67–1.03]; p > 0.05). The effect of semaglutide on hsCRP was partially mediated (20.6–61.8%) by change in HbA 1c and BW. Conclusions Semaglutide reduced hsCRP ratios-to-baseline versus comparators in subjects with type 2 diabetes (not significant with CKD). This effect was partially mediated via reductions in HbA 1c and BW and potentially by a direct effect of semaglutide. Semaglutide appears to have an anti-inflammatory effect, which is being further investigated in ongoing trials. Trial registrations: ClinicalTrials.gov identifiers: NCT01885208 (first registered June 2013), NCT02906930 (first registered September 2016), NCT02863328 (first registered August 2016), NCT02827708 (first registered July 2016).

Overview

CoChat Summary

TL;DR

In exploratory patient-level analyses of SUSTAIN 3 and PIONEER 1, 2, and 5, semaglutide reduced high-sensitivity C-reactive protein (hsCRP) ratios-to-baseline versus comparators in subjects with type 2 diabetes, except versus placebo in PIONEER 5 (CKD). The effect was partially mediated by reductions in HbA1c and body weight, with evidence suggesting a possible direct anti-inflammatory effect.

Key findings

  • Semaglutide significantly reduced hsCRP versus comparators in SUSTAIN 3, PIONEER 1, and PIONEER 2: SUSTAIN 3 semaglutide 1.0 mg vs exenatide ER 2.0 mg reduced hsCRP by 25% (ETR 0.75 [95% CI 0.65–0.88]; p < 0.001); PIONEER 1 oral semaglutide 7 mg and 14 mg vs placebo reduced by 28% and 24% (ETR 0.72 [0.59–0.89]; p < 0.01 and 0.76 [0.62–0.93]; p < 0.01); PIONEER 2 semaglutide 14 mg vs empagliflozin 25 mg reduced by 30% (ETR 0.70 [0.61–0.80]; p < 0.0001).
  • In PIONEER 5 (type 2 diabetes with CKD), oral semaglutide vs placebo showed a nonsignificant trend: ETR 0.83 [95% CI 0.67–1.03]; p = 0.08.
  • Mediation analyses showed the effect of semaglutide on hsCRP was partially mediated by change in HbA1c (18.5–35.6%), change in body weight (5.7–57.0%), and combined HbA1c and body weight (20.6–61.8%).
  • Geometric mean baseline hsCRP was similar across trials (range 2.7–3.0 mg/L).

Methods

  • Exploratory patient-level analyses of phase 3 randomized trials with hsCRP data: SUSTAIN 3 and PIONEER 1, 2, and 5. Subjects with type 2 diabetes (N = 2482) received semaglutide (n = 1328) or comparators (placebo, n = 339; exenatide extended-release, n = 405; empagliflozin, n = 410); 2471 of 2482 randomized subjects (99.6%) had baseline hsCRP and were included. Treatment durations were 56 weeks (SUSTAIN 3), 52 weeks (PIONEER 2), and 26 weeks (PIONEER 1 and 5); PIONEER 5 enrolled subjects with CKD (eGFR 30–59 mL/min/1.73 m²).
  • hsCRP ratios to baseline at end-of-treatment were analyzed using mixed models for repeated measurements (MMRM) with log-transformed hsCRP, treatment arm as fixed effect, baseline log hsCRP as covariate, nested within visit. Subgroup analyses included baseline hsCRP clinical cutoffs (< 1.0, ≥ 1.0 to ≤ 3.0, > 3.0 mg/L), hsCRP tertiles, sex, statin use, and eGFR.
  • Mediation analyses assessed change in HbA1c and/or body weight as mediators of the semaglutide effect on hsCRP, separately and combined, for pooled semaglutide arms versus comparators.

Limitations

  • The paper states the analysis was exploratory, lacked hard endpoints, had low hsCRP testing frequency, lacked data on other inflammation markers, and had relatively short follow-up (26–56 weeks). Data could not be pooled across trials due to differences in trial duration, except for baseline characteristics. hsCRP data are highly variable and outliers may dominate absolute change; ratios may be overly sensitive at low baseline hsCRP. Mediation analyses did not use all mediator values and trials were not powered for mediation analyses.
  • The paper also notes no adjustment for multiplicity was performed, and some ETRs were not significant possibly due to lack of statistical power from small sample size.
  • Evident from the text: the PIONEER 5 CKD population showed a nonsignificant hsCRP reduction versus placebo, and the analysis was limited to approved maintenance doses of semaglutide.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12933-022-01585-7

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Ratios to baseline at end-of-treatment for hsCRP with semaglutide and comparators by trial. ‘On-treatment without rescue medication’ data from the full analysis set. Ratios to baseline were analyzed using a mixed model for repeated measurements with treatment as categorical fixed effect and baseline hsCRP value (log-transformed) as covariate, all nested within visit, and an unstructured residual covariance matrix on log-transformed values. CI confidence interval; exenatide ER exenatide extended-release; ETR estimated treatment ratio; hsCRP high-sensitivity C-reactive protein; N number of subjects with available hsCRP data; s.c. subcutaneous
Fig. 1 Ratios to baseline at end-of-treatment for hsCRP with semaglutide and comparators by trial. ‘On-treatment without rescue medication’ data from the full analysis set. Ratios to baseline were analyzed using a mixed model for repeated measurements with treatment as categorical fixed effect and baseline hsCRP value (log-transformed) as covariate, all nested within visit, and an unstructured residual covariance matrix on log-transformed values. CI confidence interval; exenatide ER exenatide extended-release; ETR estimated treatment ratio; hsCRP high-sensitivity C-reactive protein; N number of subjects with available hsCRP data; s.c. subcutaneousCC BY · PubMed Central
Fig. 2 Ratio to baseline at end-of-treatment for hsCRP by trial according to clinical cutoffs. Panel (a) shows SUSTAIN 3 data, panel (b) PIONEER 1 data, panel (c) PIONEER 2 data, and panel (d) PIONEER 5 data. ‘On-treatment without rescue medication’ data from the full analysis set. Ratios to baseline were analyzed using a mixed model for repeated measurements with treatment by hsCRP groups as categorical fixed effects and baseline hsCRP value (log-transformed) as covariate, all nested within visit, and an unstructured residual covariance matrix on log-transformed values. Clinical cut-offs used in this analysis were < 1.0, ≥ 1.0 to ≤ 3.0, and > 3.0 mg/L. CI confidence interval; ETR estimated treatment ratio; exenatide ER exenatide extended-release; hsCRP high-sensitivity C-reactive protein; N number of subjects with available hsCRP data; s.c. subcutaneous
Fig. 2 Ratio to baseline at end-of-treatment for hsCRP by trial according to clinical cutoffs. Panel (a) shows SUSTAIN 3 data, panel (b) PIONEER 1 data, panel (c) PIONEER 2 data, and panel (d) PIONEER 5 data. ‘On-treatment without rescue medication’ data from the full analysis set. Ratios to baseline were analyzed using a mixed model for repeated measurements with treatment by hsCRP groups as categorical fixed effects and baseline hsCRP value (log-transformed) as covariate, all nested within visit, and an unstructured residual covariance matrix on log-transformed values. Clinical cut-offs used in this analysis were < 1.0, ≥ 1.0 to ≤ 3.0, and > 3.0 mg/L. CI confidence interval; ETR estimated treatment ratio; exenatide ER exenatide extended-release; hsCRP high-sensitivity C-reactive protein; N number of subjects with available hsCRP data; s.c. subcutaneousCC BY · PubMed Central
Fig. 3 Mediation of hsCRP by change in HbA1c and/or body weight. Panel (a) shows mediation of hsCRP by HbA1c, panel (b) by body weight, and panel (c) by HbA1c and body weight combined, all according to trial and with pooled semaglutide arms versus comparators. The indirect effect is the effect of semaglutide versus comparator on change in hsCRP that was caused by its effect through change on HbA1c and/or BW. The direct effect is the effect of semaglutide versus comparator on change in hsCRP independent of change in HbA1c and/or BW. The total effect was calculated by adding the indirect effect to the direct effect. The proportion mediated was calculated by dividing the indirect effect by the total effect × 100. Data from the ‘on-treatment without rescue medication’ period. Mediation was analyzed with mixed models for repeated measurements, adjusted for relevant mediators at baseline: HbA1c (panel a), BW (panel b), BW and HbA1c (panel c); and furthermore adjusted for additional covariates at baseline: log(hsCRP), age, sex, eGFR (Chronic Kidney Disease–Epidemiology Collaboration 2009), body mass index, statins (yes/no), insulin treatment (PIONEER 5 analyses only), metformin treatment (SUSTAIN 3 and PIONEER 5 analyses only), and HbA1c (panel b only). Mediator data were only taken from the visits where hsCRP was assessed for estimation of the direct effect. BW body weight; CI confidence interval; eGFR estimated glomerular filtration rate; HbA1c glycated hemoglobin; hsCRP high-sensitivity C-reactive protein
Fig. 3 Mediation of hsCRP by change in HbA1c and/or body weight. Panel (a) shows mediation of hsCRP by HbA1c, panel (b) by body weight, and panel (c) by HbA1c and body weight combined, all according to trial and with pooled semaglutide arms versus comparators. The indirect effect is the effect of semaglutide versus comparator on change in hsCRP that was caused by its effect through change on HbA1c and/or BW. The direct effect is the effect of semaglutide versus comparator on change in hsCRP independent of change in HbA1c and/or BW. The total effect was calculated by adding the indirect effect to the direct effect. The proportion mediated was calculated by dividing the indirect effect by the total effect × 100. Data from the ‘on-treatment without rescue medication’ period. Mediation was analyzed with mixed models for repeated measurements, adjusted for relevant mediators at baseline: HbA1c (panel a), BW (panel b), BW and HbA1c (panel c); and furthermore adjusted for additional covariates at baseline: log(hsCRP), age, sex, eGFR (Chronic Kidney Disease–Epidemiology Collaboration 2009), body mass index, statins (yes/no), insulin treatment (PIONEER 5 analyses only), metformin treatment (SUSTAIN 3 and PIONEER 5 analyses only), and HbA1c (panel b only). Mediator data were only taken from the visits where hsCRP was assessed for estimation of the direct effect. BW body weight; CI confidence interval; eGFR estimated glomerular filtration rate; HbA1c glycated hemoglobin; hsCRP high-sensitivity C-reactive proteinCC BY · PubMed Central

Verification

Claims the paper makes

21 Valid · 0 Not valid · 6 Not checked · 64 Own results and interpretations

27 more claims

Create a free account to see all 91 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 37
  • It may state two separate claims as one. 39

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 47 references

Cited by

See all 91

Metadata

Authors
Mosenzon, O., Capehorn, M. S., De Remigis, A., Rasmussen, S., Weimers, P., & Rosenstock, J.
Affiliations
  • Hebrew University of Jerusalem (IL)
  • The Rotherham NHS Foundation Trust (GB)
  • Novo Nordisk (Denmark) (DK)
  • Velocity Clinical Research (United States) (US)
Corresponding author
Mosenzon, Ofri
Venue
Cardiovascular Diabetology
Published
2022-09-02
Volume
21
Issue
1
Pages
172-172
ISSN
1475-2840 (ISSN-L)
OpenAlex
W4294542663
Cited by
91
References
47
Citations by year
2026: 35 · 2025: 28 · 2024: 15 · 2023: 12 · 2022: 1
FWCI
10.37
Type
journal article
Language
en
Open access
Licence
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
semaglutide, high-sensitivity C-reactive protein, type 2 diabetes, anti-inflammatory activity, HbA1c, body weight, mediation analysis, chronic kidney disease, exenatide extended-release, empagliflozin, SUSTAIN trials, PIONEER trial, GLP-1 receptor agonists, estimated glomerular filtration rate
MeSH terms
Semaglutide, Body Weight, C-Reactive Protein, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glycated Hemoglobin, Humans, Randomized Controlled Trials as Topic, Treatment Outcome, Renal Insufficiency, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials. https://app.cochat.ai/papers/10.1186/s12933-022-01585-7
The paper
Mosenzon, O., Capehorn, M. S., De Remigis, A., Rasmussen, S., Weimers, P., & Rosenstock, J. (2022). Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-022-01585-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.